Lost Ground: Cancer Screening in the COVID-19 Era
A pandemic-related drop in cancer diagnoses could spell long-term trouble for patients and providers.
Top of the News-dtet
Simplifying At-Home Tests with AI
A new assay uses AI-optimized enzymes to simplify and increase the accuracy of rapid pathogen detection.
Investigating the Cause of the 2022 Severe Acute Hepatitis Outbreak in Children
AAV2 virus detected with metagenomics, TE sequencing, and PCR in non-A–E hepatitis cases from two cohorts in Scotland/the UK and the US.
New Federal Taskforce to Speed Implementation of Emergency Use Diagnostics
From - Diagnostic Testing & Emerging Technologies
Three federal agencies announced the creation of a new taskforce to provide timely recommendations to laboratories for rapid implementation of…
Genetic Risk of Prostate Cancer Underestimated; Testing Guidelines Miss Men With Elevated Prostate Cancer Risk
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
New Studies Question Utility of Gene Expression Testing for Cancers With Unknown Primary Site, Low-Risk Breast Cancer
From - Diagnostic Testing & Emerging Technologies
Gene expression profiling has been making inroads into clinical cancer care, with application in cancer classification, most notably with…
Diagnostics Sector Saw Increased Investment, Exits in 2018
From - Diagnostic Testing & Emerging Technologies
Life science and health care companies had a banner year in 2018, with a record-breaking year for venture capital investment…
Newborn Sequencing Delivers Some Unanticipated Findings
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
New Broad All-Payor Kickback Law Impacting Laboratories, Commission-based Compensation and more
Most Oncologists Report Using Sequencing-Based Panels In Practice
From - Diagnostic Testing & Emerging Technologies
The majority of U.S. oncologists report using next-generation sequencing-based (NGS-based) tests to guide patient care, according to a study published…
Big Data Can Reshape Lab Reference Values in the Era of Personalized Medicine
From - Diagnostic Testing & Emerging Technologies
As might be expected, there are substantial differences in "normal" laboratory values determined by healthy outpatients and critically ill patients in…
Despite 23andMe Authorization, FDA Cautious About PGx Testing
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
FDA Enabling New Point-of-Care Tests for Ebola Outbreak, Flu Season
From - Diagnostic Testing & Emerging Technologies
Several recent U.S. Food and Drug Administration (FDA) actions are bringing point-of-care (POC) infectious disease tests closer to…